AI Article Synopsis
- - Chronic stable angina impacts 6-7 million Americans, leading to reduced quality of life and life expectancy, with existing treatments like β-blockers and calcium channel blockers sometimes being ineffective or intolerable for patients.
- - New treatment options are being explored that address the limitations of current medications, particularly those targeting specific ionic currents involved in heart function, including ranolazine, which acts on the late Na current.
- - Research continues to investigate ranolazine's potential not just for chronic angina, but also for preventing arrhythmias and treating heart failure, alongside the development of new derivatives with unique therapeutic effects.
Article Abstract
Chronic stable angina affects 6-7 million Americans and contributes to a significant reduction in quality of life and life expectancy. Current pharmacotherapy for reducing episodes of exertional angina includes β-blockers, calcium channel blockers and long-acting nitrates. Patients may have contraindications to the use of one or more of these agents or be unable to tolerate initial or larger therapeutic doses. As a result of the inability of current management strategies to optimally control episodes of chronic angina, new therapies have been investigated that do not have some of the limitations of current therapies. New therapies for chronic stable angina are based on a mechanism involving membrane current such as the funny current and the late Na current. Ranolazine (Ran) is an antianginal drug acting on I(Na). After its current indication in the chronic stable angina, the role of this molecule is still being studied for prophylaxis of certain arrhythmias and treatment of heart failure. Moreover, have been recently developed new interesting patents of novel pharmaceutical effects and derivates of Ran.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/157489011797377103 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Daily Path Areas and Location Use During and After Cardiac Rehabilitation.
J Cardiopulm Rehabil Prev
January 2025
Author Affiliations: Faculty of Health, Dalhousie University, Halifax, Nova Scotia, Canada (Ms Langley); Bluewater Health, Sarnia, Ontario, Canada and School of Kinesiology (Exercise and Health Psychology Lab), Western University, London, Ontario, Canada (Dr Campbell); Physical Activity and Chronic Disease Prevention Unit, University of British Columbia, Vancouver, British Columbia, Canada(Dr Warburton); School of Exercise Science, Physical and Health Education, Faculty of Health, University of Victoria, Victoria, British Columbia, Canada (Dr Rhodes); Department of Kinesiology & Physical Education, McGill University, Montreal, Quebec, Canada (Dr Sweet); Department of Medicine, Division of Cardiology, Dalhousie University, Halifax, Nova Scotia, Canada (Dr Giacomantonio); School of Health and Human Performance and the Healthy Populations Institute, Dalhousie University, Halifax, Nova Scotia, Canada (Dr Rainham); Faculty of Kinesiology & Recreation Management, University of Manitoba, Winnipeg, Manitoba, Canada (Dr Strachan); Department of Applied Human Sciences, University of Prince Edward Island, Charlottetown, Prince Edward Island, Canada (Dr Saunders); and Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada (Dr Blanchard).
Purpose: Little research has focused on the potential impact that the environment plays in shaping cardiac rehabilitation (CR) patient sedentary time (ST) and physical activity (PA). To address this, the current study generated daily path areas (DPAs) based on the locations they visited during and after they completed CR.
Methods: Patients in CR (n = 66) completed a survey and wore an accelerometer and Global Positioning System receiver for 7 days early (first month), late (last 2 weeks of program), and 3 months after completing CR.
Integrating machine learning and structural dynamics to explore B-cell lymphoma-2 inhibitors for chronic lymphocytic leukemia therapy.
Mol Divers
January 2025
Department of Biotechnology, Deen Dayal, Upadhyay Gorakhpur University, Gorakhpur, India.
Chronic lymphocytic leukemia (CLL) is a malignancy caused by the overexpression of the anti-apoptotic protein B-cell lymphoma-2 (BCL-2), making it a critical therapeutic target. This study integrates computational screening, molecular docking, and molecular dynamics to identify and validate novel BCL-2 inhibitors from the ChEMBL database. Starting with 836 BCL-2 inhibitors, we performed ADME and Lipinski's Rule of Five (RO5) filtering, clustering, maximum common substructure (MCS) analysis, and machine learning models (Random Forest, SVM, and ANN), yielding a refined set of 124 compounds.
View Article and Find Full Text PDFThe Effect of the Size of Gold Nanoparticle Contrast Agents on CT Imaging of the Gastrointestinal Tract and Inflammatory Bowel Disease.
Bioconjug Chem
January 2025
Biochemistry and Molecular Biophysics, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States.
Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD). CT imaging with contrast agents is commonly used for visualizing the gastrointestinal (GI) tract in UC patients. Contrast agents that provide enhanced imaging performance are highly valuable in this field.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Background: Oxidative stress, which refers to an imbalance between the production of reactive oxygen/nitrogen species (ROS/RNS) and the body's antioxidant defense mechanisms, is implicated in the pathogenesis of various chronic diseases by promoting cellular damage, inflammation, and dysfunction. Numerous methods have been reported for detecting ROS/RNS in vitro and in vivo; however, detecting methods for the secondary products of the ROS/RNS reactions, particularly quasi-stable oxidized products, have been much less explored.
Method: In this report, we discovered that acetylacetone, a core moiety of curcumins, is a new scaffold for generating chemiluminescence in the presence of oxidants.
Biomarkers.
Alzheimers Dement
December 2024
Washington University in St. Louis, Saint Louis, MO, USA.
Background: Alzheimer disease (AD) is a chronic progressive neurodegenerative disorder that presents with cognitive dysfunction, memory loss, language difficulties, emotion dysregulation, and the eventual loss of motor function and death. Magnetic resonance imaging (MRI) shows early atrophy in the medial temporal lobes, which then spreads to the posterior temporal lobe, parietal lobe, and finally the frontal lobe with relative sparing of the sensorimotor cortex. Social disadvantage has been shown to have potentially additive impacts on aging trajectories.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!